Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HCC

- PMLiVE

Lilly’s Cyramza disappoints in liver cancer

Fails to improve overall survival by significant margin

- PMLiVE

Eisai resubmits Fycompa to G-BA for pricing assessment

But German distribution of epilepsy drug remains on hold until reimbursement settled

Biogen Idec building

Eisai and Biogen partner on Alzheimer’s

Will co-develop two drug candidates

- PMLiVE

Germany looks again at Fycompa pricing

Eisai's epilepsy drug could be re-entered onto market

- PMLiVE

Public unaware of main cause of liver cancer

Janssen-backed survey finds one in six people is aware of viral hepatitis role in the disease

- PMLiVE

Eisai doubles Belviq’s US sales force

Will take on more than 200 new contact sales reps to promote obesity drug

- PMLiVE

Eisai expands in Europe with new Belgium business

Will coordinate local reimbursement for cancer drug Halaven

- PMLiVE

Eisai launches Halaven in Russia

Expands market reach of its breast cancer drug to cover emerging market

- PMLiVE

Eisai lines-up Fycompa access programme for Germany

But sales suspension for epilepsy drug will continue

- PMLiVE

Eisai launches online obesity awareness drive

Wants US employers to realise the cost of obesity

- PMLiVE

Eisai sues DEA over Fycompa scheduling

Pharma company won FDA approval in 2012 but still lacks DEA verdict

Novartis building

Novartis says Afinitor fails liver cancer trial

Halts plans to file for approval in new indication

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links